News | Cardio-oncology | May 06, 2016

SCAI Releases Expert Consensus on Cath Lab Treatment for Cardio-Oncology Patients

Document reviews current practices for care of patients facing concomitant cardiovascular disease and cancer

May 6, 2016 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus statement providing cardiologists, oncologists and internal medicine physicians guidance for treating patients facing concomitant cardiovascular disease and cancer. The document, “SCAI Expert Consensus Statement: Evaluation, Management, and Special Considerations of Cardio-Oncology Patients in the Cardiac Catherization Laboratory,” was released in Catheterization and Cardiovascular Interventions (CCI), and is endorsed by the Cardiological Society of India (CSI) and Sociedad Latino Americana de Cardiologia Intervencionista (SOLACI). The paper aims to increase the competency of cardiovascular professionals providing care to cancer patients.

Advances in cancer therapy have resulted in steady decline in cancer-related mortality since the 1990s. According to the Centers for Disease Control and Prevention, there are approximately 14.5 million cancer survivors in the United States, and this number is expected to increase to 20 million in 2020. In view of these trends, the need for invasive evaluation and management in the cardiac catheterization laboratory for such patients has increased.

“Little data exists as cancer patients have been excluded from national percutaneous coronary interventions (PCI) registries and from most randomized trials involving PCI,” said Cezar A. Iliescu, M.D., FSCAI, lead author of the document and director of the Cardiac Catheterization Laboratory at MD Anderson Cancer Center in Houston, Texas. “Therefore, SCAI commissioned a consensus group to define the landscape and provide recommendations based on the available published medical literature and the expertise of operators with accumulated experience in the cardiac catheterization of cancer patients.”

Cancer is associated with a hypercoagulable state, which increases the risk of acute thrombotic events. Cancer therapies can cause significant injury to the vasculature, resulting in angina, acute coronary syndromes, arrhythmias and heart failure, even independently from a direct myocardial effect.

The document highlights the review of the mechanisms of vascular toxicities in cancer patients (radiation- or chemotherapy-induced). It also covers several other aspects of cardiovascular care such as screening and cardio-protection, as well as PCI in patients with thrombocytopenia and anemia, fractional flow reserve, intravascular ultrasound and optical coherence tomography for complex intravascular assessment and deferring stenting, if possible. The paper also includes non-coronary interventional procedures in cancer patients like endomyocardial biopsy and pericardiocentesis, as well as aortic valvuloplasty and transcatheter aortic valve implantation.

Cardio-oncology is expected to have continued growth in the coming years. Several healthcare institutions have founded onco-cardiology/cardio-oncology departments, along with fellowship training programs focusing on the cardiology subspecialty.

For more information: www.onlinelibrary.wiley.com

Related Content

Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Being Overweight May Change Young Adults' Heart Structure, Function
News | Cardiac Diagnostics | August 03, 2018
Even as a young adult, being overweight may cause higher blood pressure and thicken heart muscle, setting the stage for...
High Intensity Exercise in Teenagers Could Ward Off Heart Disease

Ultrasound image of the carotid artery. Lines in yellow were used to determine arterial diameter and stretching before and following exercise.

News | Cardiac Diagnostics | July 16, 2018
New research published in Experimental Physiology has indicated potential differences in heart health benefits of...
News | Cardiac Diagnostics | June 14, 2018
A team of researchers says it has linked sensitivity to an allergen in red meat to the buildup of plaque in the...
The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

The blood of patients with familial chylomicronemia syndrome (FCS) can appear milky in color (lipemic) due to the buildup of fat in their body. Image courtesy of Akcea Therapeutics.

 

Feature | Cardiac Diagnostics | May 07, 2018 | Steven D. Freedman, M.D., Ph.D.
 
Overlay Init